Frequency of Depression and Anxiety in Patients With Lung Cancer Undergoing Chemotherapy: A Single-Center, Cross-Sectional Study From Vietnam

Background Chemotherapy is a crucial component of multimodality treatment for lung cancer patients. Although considered a vital and effective approach, chemotherapy can induce adverse effects, negatively impacting patients' quality of life. These adverse effects can also lead to psychological issues, particularly depression and anxiety. This study aimed to determine the frequency of depression, anxiety, and their associated factors in patients with lung cancer undergoing chemotherapy. Methodology A cross-sectional study was conducted on 92 patients with lung cancer receiving chemotherapy at the University Medical Center Ho Chi Minh City, Vietnam, from February to May 2023. The patients' depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results Among 92 patients with a mean age of 60.4 +/- 9.6 years and 58 males (63%), the prevalence of depression was 44.5% (41 patients), with significant associations between depression and gender, economic status, smoking status, and performance status. The prevalence of anxiety was 38% (35 patients), with significant associations between anxiety and gender, chemotherapy cycle, cancer stage, and performance status. Conclusions Our study highlights the importance of a multidisciplinary approach to cancer care, ensuring that lung cancer patients receive the necessary support to manage both physical and mental health challenges throughout chemotherapy.